Neuralink has claimed in a tweet that it has finally received approval from the FDA to start a first-in-human clinical trial of its brain implant chip – but hasn’t indicated when it may start.

Your donation makes it possible for us to keep doing ... cyber attacks. Neuralink said it now plans to add improved functionality to the brain implants used in the human trials, developing new ...

Musk's Neuralink Says Second Trial Implant Went Well, No Thread Retraction Issue (Reuters) - Elon Musk's brain technology startup Neuralink said its implant, designed to allow paralyzed patients ...

Elon Musk-owned neurotechnology firm Neuralink announced ... that the surgery for the second trial participant “went well” at the Barrow Neurological Institute in Phoenix, Arizona, last ...

Neuralink reported that its brain implant functioned effectively in a second trial patient ... and is equipped with over 1,000 electrodes that help it to read neuron activity in the brain and ...

SAN FRANCISCO - Neuralink Corp, Mr Elon Musk’s brain-computer company, said surgery for its second implant in a human “went well ... the Barrow Neurological Institute in Phoenix, one ...

The technology isn't new, and multiple companies have performed human trials in the past with varying degrees of success. That said, Neuralink's design decisions could advance the technology.

Aug 21 (Reuters) - Elon Musk's brain technology startup Neuralink said its implant, designed to allow paralyzed patients to use digital devices by thinking alone, is working well in a second trial ...

Elon Musk's Neuralink has made progress with its brain implant technology, designed to aid paralyzed patients in controlling digital devices via thought. In a second trial, patient Alex showed no ...

Elon Musk's brain technology startup Neuralink said its implant, designed to allow paralyzed patients to use digital devices by thinking alone, is working well in a second trial patient.

Elon Musk's brain technology startup Neuralink said its implant, designed to allow paralysed patients to use digital devices by thinking alone, is working well in a second trial patient.